Sang-Hoon Kim
Präsident bei BUKWANG PHARMACEUTICAL CO., LTD.
Vermögen: 3 Mio $ am 30.04.2024
Profil
Sang-Hoon Kim is currently working as the Co-President, Director & Chief Strategy Officer at Bukwang Pharmaceutical Co., Ltd.
He is also a Director at Contera Pharma ApS and Dyna Therapeutics Co., Ltd.
Mr. Kim completed his undergraduate degree at Boston University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2022 | 568 504 ( 0,83% ) | 3 Mio $ | 30.04.2024 |
Aktive Positionen von Sang-Hoon Kim
| Unternehmen | Position | Beginn |
|---|---|---|
| BUKWANG PHARMACEUTICAL CO., LTD. | Präsident | 15.03.2013 |
Contera Pharma ApS
 Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Direktor/Vorstandsmitglied | - |
| Dyna Therapeutics Co., Ltd. | Direktor/Vorstandsmitglied | - |
Ausbildung von Sang-Hoon Kim
| Boston University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BUKWANG PHARMACEUTICAL CO., LTD. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
| Dyna Therapeutics Co., Ltd. |
